Compare PCRX & ADSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | ADSE |
|---|---|---|
| Founded | 2006 | 1980 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 949.9M | 900.0M |
| IPO Year | 2010 | 2021 |
| Metric | PCRX | ADSE |
|---|---|---|
| Price | $24.59 | $11.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $30.25 | N/A |
| AVG Volume (30 Days) | ★ 636.8K | 16.0K |
| Earning Date | 04-30-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $6.78 | $549.86 |
| Revenue Next Year | $8.54 | N/A |
| P/E Ratio | $129.84 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $7.89 |
| 52 Week High | $27.66 | $13.50 |
| Indicator | PCRX | ADSE |
|---|---|---|
| Relative Strength Index (RSI) | 49.55 | 40.64 |
| Support Level | $24.61 | $10.98 |
| Resistance Level | $25.06 | $12.02 |
| Average True Range (ATR) | 0.91 | 0.39 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 47.59 | 36.17 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. The company generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.